Do more HMOs translate into increased benefits?

The more we learn about human milk oligosaccharides (HMOs), the greater the evidence becomes that they are essential for  balanced nutrition during infancy. Since approximately 5 years ago it became possible to industrially produce 2’fucosyllactose (2’FL), in an identical structure to the 2’FL present in mother’s milk. As could be predicted, more HMOs can now be synthetized, resulting in the availability of blend of 5 HMOs (2’FL, difucosyllactose (DFL), Lacto-N-tetraose (LNT), 3’-Sialyllactose (3’SL) which have been shown to be safe and well tolerated in infants.